End-of-day quote
Other stock markets
|
||
- USD | - |
21/05 | Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise | MT |
17/05 | Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study | CI |
Sales 2024 * | 596K 49.62M | Sales 2025 * | 975K 81.17M | Capitalization | 38.53M 3.21B |
---|---|---|---|---|---|
Net income 2024 * | -5M -416M | Net income 2025 * | -7M -583M | EV / Sales 2024 * | 64.6 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 39.5 x |
P/E ratio 2024 * |
-6.64
x | P/E ratio 2025 * |
-6.57
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.23% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 26/06/26 | |
John Docherty
PSD | President | 53 | 15/15/15 |
George Jurcic
IRC | Investor Relations Contact | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 26/06/26 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 08/11/08 |
Albert Reese
BRD | Director/Board Member | 74 | 14/21/14 |
1st Jan change | Capi. | |
---|---|---|
+37.78% | 723B | |
+32.82% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+16.64% | 244B | |
-4.13% | 208B | |
+10.63% | 210B | |
+9.32% | 169B |